Cereno Scientific enters rare disease space with lead drug candidate CS1
Cereno Scientific today announced that the company will advance the development of drug candidate CS1 as an epigenetic modulator of rare diseases with orphan drug potential. The initial focus will be on pulmonary arterial hypertension (PAH), a form of high blood pressure in the lungs. The company’s revised clinical development strategy for CS1 was formed together with top commercial, scientific and regulatory advisors in Europe and the US with insights from the American authority, US FDA. A Phase II study program is planned to be started during first half of 2021.The clinical development